Merck (NYSE:MRK) reported a series of positive late stage clinical trial results for oncology and HIV therapies, including ...

After its latest pipeline clear-out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through ...

In the latest close session, Merck (MRK) was up +1.14% at $117.11. The stock's performance was ahead of the S&P 500's daily gain of 0.83%. At the same time, the Dow added 0.5%, and the tech-heavy ...

Merck said on Monday it would split its business into two, creating ⁠a division for its cancer franchise while grouping its ​non-oncology treatments separately.

The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...

Merck pharmaceutical operations, vaccines, oncology medicines, and global research presence within the s&p 500 healthcare sector, highlighting development, manufacturing, and distribution activities ...

Merck KGaA (MKGAF) stock drops as the company projects a disappointing revenue and adjusted EBITDA outlook for 2026. Read ...

Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.

The drugmaker is splitting up its Human Health business before patent protection on its blockbuster treatment Keytruda expires in two years.

Merck KGaA forecast a sluggish year ahead, with the possibility of falling profits, as generic competition for its multiple ...

The company anticipates currency headwinds would continue to weigh on its earnings this year, as the life-sciences and ...

A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...